What is Cancer News Daily?

Cancer News Daily is a comprehensive cancer research news aggregator that collects and curates the latest research articles from 120+ trusted medical journals and cancer research institutions worldwide. We provide free access to breakthrough treatments, clinical trials, nutrition research, and new technology in oncology.

How often is content updated?

Our automated system fetches new cancer research articles every 2 hours from 120+ authoritative medical journals across 5 continents, ensuring you always have access to the latest breakthroughs.

What sources does Cancer News Daily aggregate from?

We aggregate content from 120+ trusted sources including top-tier journals like Nature Cancer, The Lancet Oncology, JAMA Oncology, Cancer Cell, major cancer centers like MD Anderson and Memorial Sloan Kettering, government organizations like NCI and NIH, and international research institutions across North America, Europe, Asia-Pacific, and beyond.

Is Cancer News Daily free to use?

Yes, Cancer News Daily is completely free to access. We believe life-saving cancer research should be accessible to everyone - patients, caregivers, researchers, and medical professionals worldwide.

The East and West consolidated efficacy of radioligand therapy in neuroendocrine tumors

Annals of Oncology | November 7, 2025 | R.P. Riechelmann, R. Garcia-Carbonero

Radioligand therapy (RLT), primarily and currently represented by 177Lutetium-Oxodotrotate (177Lu-DOTATATE), a somatostatin receptor (SST)-targeted beta- and gamma-emitting radioligand, is recommended in guidelines to treat patients with metastatic gastroenteropancreatic (GEP) SST-positive neuroendocrine tumors (NET).1-3 Level 1 evidence to endorse RLT in GEP NETs derive from two pivotal phase III clinical trials: NETTER-14 and NETTER-2.5 In NETTER-1, patients with metastatic grade (G)…

Topics: clinical-trials

Read the full article at Annals of Oncology